Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004067524 - EP4 RECEPTOR ANTAGONISTS

Publication Number WO/2004/067524
Publication Date 12.08.2004
International Application No. PCT/GB2004/000347
International Filing Date 29.01.2004
IPC
C07D 307/54 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02not condensed with other rings
34having two or three double bonds between ring members or between ring members and non-ring members
38with substituted hydrocarbon radicals attached to ring carbon atoms
54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 307/68 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02not condensed with other rings
34having two or three double bonds between ring members or between ring members and non-ring members
56with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 405/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 407/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
407Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/183
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 409/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 411/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
411Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 13/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
A61P 15/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
10for impotence
A61P 19/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Applicants
  • PHARMAGENE LABORATORIES LIMITED [GB]/[GB] (AllExceptUS)
  • CLARK, David, Edward [GB]/[GB] (UsOnly)
  • CLARK, Kenneth, Lyle [GB]/[GB] (UsOnly)
  • COLEMAN, Robert, Alexander [GB]/[GB] (UsOnly)
  • DAVIS, Richard, Jon [GB]/[GB] (UsOnly)
  • FENTON, Garry [GB]/[GB] (UsOnly)
  • HARRIS, Neil, Victor [GB]/[GB] (UsOnly)
  • HYND, George [GB]/[GB] (UsOnly)
  • NEWTON, Christoper, Gregory [GB]/[GB] (UsOnly)
  • OXFORD, Alexander, William [GB]/[GB] (UsOnly)
  • STUTTLE, Keith, Alfred, James [GB]/[GB] (UsOnly)
  • SUTTON, Jonathan, Mark [GB]/[GB] (UsOnly)
Inventors
  • CLARK, David, Edward
  • CLARK, Kenneth, Lyle
  • COLEMAN, Robert, Alexander
  • DAVIS, Richard, Jon
  • FENTON, Garry
  • HARRIS, Neil, Victor
  • HYND, George
  • NEWTON, Christoper, Gregory
  • OXFORD, Alexander, William
  • STUTTLE, Keith, Alfred, James
  • SUTTON, Jonathan, Mark
Agents
  • WATSON, Robert
Priority Data
0302094.829.01.2003GB
60/443,87231.01.2003US
60/509,52109.10.2003US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) EP4 RECEPTOR ANTAGONISTS
(FR) ANTAGONISTES AUX RECEPTEURS EP4
Abstract
(EN) Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.
(FR) L'invention concerne des composés de formule (I), dans laquelle R2 désigne H ou un groupe alkyle en C1-4 éventuellement substitué ; Y représente soit -(CH2)n-X-, où n égale 1 ou 2 et X désigne O, S, S(=O), S(=O)2, soit NRN1, où RN1 est sélectionné parmi H ou alkyle en C1-4 éventuellement substitué, ou bien Y représente -C(=O)NRN2-, où RN2 est sélectionné parmi H, et alkyle en C1-7 ou aryle en C5-20 éventuellement substitués ; R3 est un groupe aryle en C6 éventuellement substitué lié à un autre groupe aryle en C6 éventuellement substitué, si les deux groupes aryles en C6 sont des cycles benzéniques, un pont oxygène pouvant être placé entre les deux cycles, lié de façon adjacente à la liaison sur les deux cycles ; A est une liaison simple ou un groupe alkylène en C1-3 et R5 désigne soit (i) carboxy, soit (ii) un groupe de formule (II), soit (iii) un groupe de formule (III), formules dans lesquelles R représente alkyle en C1-7, aryle en C5-20 ou NRN3RN4 éventuellement substitués, RN3 et RN4 étant sélectionnés indépendamment parmi alkyle en C1-4 éventuellement substitué, (iv) tétrazol-5-yle.
Latest bibliographic data on file with the International Bureau